Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis C, Chronic | 4 | 2019 | 973 | 0.39 | Why? |
| Liver Cirrhosis | 3 | 2019 | 1810 | 0.24 | Why? |
| Fusobacterium | 1 | 2021 | 19 | 0.23 | Why? |
| Fusobacterium Infections | 1 | 2021 | 37 | 0.22 | Why? |
| N-Acetylneuraminic Acid | 1 | 2021 | 198 | 0.19 | Why? |
| Pneumocystis carinii | 1 | 2021 | 205 | 0.19 | Why? |
| Hepatitis C Antibodies | 1 | 2019 | 120 | 0.18 | Why? |
| Mucin-1 | 1 | 2021 | 277 | 0.18 | Why? |
| Herpesvirus 2, Human | 1 | 2018 | 137 | 0.17 | Why? |
| Erectile Dysfunction | 1 | 2018 | 141 | 0.16 | Why? |
| Pneumonia, Pneumocystis | 1 | 2021 | 322 | 0.16 | Why? |
| Peritonitis | 1 | 2018 | 217 | 0.15 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.15 | Why? |
| Herpesvirus 1, Human | 1 | 2018 | 286 | 0.15 | Why? |
| Herpes Simplex | 1 | 2018 | 272 | 0.14 | Why? |
| Vitamin D Deficiency | 2 | 2019 | 1782 | 0.14 | Why? |
| Lymphocyte Subsets | 1 | 2020 | 987 | 0.13 | Why? |
| Genotype | 3 | 2019 | 4697 | 0.11 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.11 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.11 | Why? |
| Hepacivirus | 2 | 2019 | 1509 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.11 | Why? |
| Microbiota | 1 | 2021 | 1240 | 0.10 | Why? |
| Autism Spectrum Disorder | 1 | 2018 | 587 | 0.10 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.09 | Why? |
| Thrombophilia | 1 | 2021 | 1935 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Liver Neoplasms | 1 | 2019 | 1666 | 0.08 | Why? |
| Point-of-Care Testing | 1 | 2019 | 2782 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Saliva | 1 | 2019 | 4679 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2019 | 7218 | 0.05 | Why? |
| Immunocompetence | 1 | 2021 | 280 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Lymphocyte Count | 2 | 2021 | 4758 | 0.05 | Why? |
| Phosphodiesterase Inhibitors | 1 | 2018 | 61 | 0.05 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2019 | 378 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Genome, Viral | 1 | 2018 | 13157 | 0.04 | Why? |
| Mouth | 1 | 2021 | 622 | 0.04 | Why? |
| Prevalence | 4 | 2018 | 25773 | 0.04 | Why? |
| Antiviral Agents | 2 | 2019 | 41703 | 0.04 | Why? |
| Male | 13 | 2021 | 367725 | 0.04 | Why? |
| Aged | 10 | 2021 | 215776 | 0.04 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Dried Blood Spot Testing | 1 | 2018 | 383 | 0.04 | Why? |
| Italy | 4 | 2021 | 38444 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2019 | 14232 | 0.03 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2019 | 1654 | 0.03 | Why? |
| Female | 11 | 2021 | 380317 | 0.03 | Why? |
| Vitamin D | 2 | 2019 | 2904 | 0.03 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.03 | Why? |
| Humans | 16 | 2021 | 930598 | 0.03 | Why? |
| Precision Medicine | 1 | 2020 | 1477 | 0.03 | Why? |
| Feasibility Studies | 1 | 2019 | 3467 | 0.02 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.02 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Liver | 1 | 2019 | 4007 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.01 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Adult | 2 | 2021 | 244371 | 0.01 | Why? |
| Treatment Outcome | 1 | 2019 | 51732 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |